Eslicarbazepine Acetate Tablet
Product Images NDC 68180-292

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 68180-292). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (7bec3041 E111 4903 9313 5cf4179d2aad 01)

Chemical structure diagram of Eslicarbazepine Acetate, showing its molecular framework with numbered carbon atoms and functional groups including an acetate moiety and amide group.*

FDA Label Image

Figure 2 (7bec3041 E111 4903 9313 5cf4179d2aad 02)

A chart depicting the fold change and 90% confidence interval for eslicarbazepine levels relative to reference based on various factors including age (≥ 65 years), gender (female), hepatic impairment (mild, moderate, severe), and renal impairment (mild, moderate, severe). Recommendations for dose adjustments are provided, with no dose adjustment needed for age ≥ 65, female gender, mild/moderate hepatic impairment, and mild renal impairment. Dose reductions are recommended for moderate and severe renal impairment, while severe hepatic impairment is not studied.*

FDA Label Image

Figure 3 (7bec3041 E111 4903 9313 5cf4179d2aad 03)

A data table depicting fold change and 90% confidence intervals for eslicarbazepine acetate interactions relative to various reference drugs including carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproate. The table also provides dosing recommendations for eslicarbazepine acetate adjustments based on these interactions.*

FDA Label Image

Figure 4 (7bec3041 E111 4903 9313 5cf4179d2aad 04)

Chart depicting fold change with 90% confidence intervals for various antiepileptic drugs (AEDs) and corresponding dosing recommendations. Drugs like carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproate are listed with fold change values on the x-axis, along with notes indicating potential dose adjustments, especially for phenytoin, which requires plasma level monitoring.*

FDA Label Image

Figure 5 (7bec3041 E111 4903 9313 5cf4179d2aad 05)

A chart showing fold change with 90% confidence intervals for various drugs affected by Eslicarbazepine Acetate. It includes non-AEDs like Digoxin and Metformin, statins (Simvastatin, Rosuvastatin), oral contraceptives (Ethinylestradiol, Levonorgestrel), and Warfarin variants (S-Warfarin, R-Warfarin). Recommendations for dose adjustments or monitoring are listed for some drugs based on lipid changes or INR levels.*

FDA Label Image

Figure 6 (7bec3041 E111 4903 9313 5cf4179d2aad 06)

A Kaplan-Meier curve graph showing exit rates (%) with 95% confidence intervals for Eslicarbazepine acetate at 1200 mg and 1600 mg doses. The graph compares results from two studies and includes sample sizes (N) for each data point. Historical control data are also displayed for reference.*

FDA Label Image

Figure 7 (7bec3041 E111 4903 9313 5cf4179d2aad 07)

A bar chart depicting the proportion of patients by reduction in seizure frequency from baseline in percentages. It compares three groups: placebo, Eslicarbazepine acetate 800 mg, and Eslicarbazepine acetate 1200 mg, across categories of seizure frequency reduction from 'Worse' to '75 to 100%'.*

FDA Label Image

Figure 8 (7bec3041 E111 4903 9313 5cf4179d2aad 08)

Label for Eslicarbazepine Acetate Tablets 200 mg by Lupin Pharmaceuticals, Inc. The label indicates a 30-tablet oral dosage form with instructions to dispense the Medication Guide. Storage and manufacturer details for Lupin Pharmaceuticals, Inc. and Lupin Limited are included, alongside an NDC barcode and a QR code linking to the medication guide.*

FDA Label Image

Figure 9 (7bec3041 E111 4903 9313 5cf4179d2aad 09)

Label for Eslicarbazepine Acetate Tablets 400 mg oral tablets by Lupin Pharmaceuticals, Inc. The label states a supply of 30 tablets with the instruction 'Once Daily' and includes storage and dispensing information. Manufactured by Lupin Limited, India, it also features a barcode and a QR code linking to medication guides.*

FDA Label Image

Figure 10 (7bec3041 E111 4903 9313 5cf4179d2aad 10)

Label for Eslicarbazepine Acetate Tablets 600 mg oral tablets, manufactured by Lupin Pharmaceuticals, Inc. The label includes the NDC number 68180-292-07, storage instructions, and a barcode. It indicates a 60-tablet count and features a QR code linking to medication guides.*

FDA Label Image

Figure 11 (7bec3041 E111 4903 9313 5cf4179d2aad 11)

Label for Eslicarbazepine Acetate Tablets 800 mg oral tablets by Lupin Pharmaceuticals, Inc. The label indicates a package size of 30 tablets, with directions to take once daily. It includes storage instructions, prescribing information references, a barcode, and a QR code for medication guides. The product is manufactured by Lupin Limited, India, for Lupin Pharmaceuticals, Inc., USA.*

FDA Label Image

Image (7bec3041 E111 4903 9313 5cf4179d2aad 216 1)

The image shows a vertical array of tablets, presumably of Eslicarbazepine Acetate, arranged in descending order from largest to smallest. The tablets are round and uniformly colored, visually representing multiple dosage strengths available from Lupin Pharmaceuticals, Inc. No text or labeling is visible on the tablets themselves.*

FDA Label Image

Image (7bec3041 E111 4903 9313 5cf4179d2aad 245 1)

Eslicarbazepine Acetate 400 mg oral tablets by Lupin Pharmaceuticals, Inc. The tablet is white, round, and has a pattern of dots arranged in clusters forming a vertical design on one face.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.